---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-237854"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:52:46.641530+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Soleno Therapeutics appoints Mark W. Hahn to Board and Audit Committee

## Summary
- Board increased to 7 seats; Hahn appointed as Class II director, term expiring at 2028 annual meeting.
- Hahn received 10,046 RSUs vesting over 3 years under Outside Director Compensation Policy.
- Hahn most recently was CFO of Verona Pharma through its acquisition by Merck for ~$10B in Oct 2025.
- Previously CFO of Dova Pharma (acquired by Sobi for up to $915M) and Cempra (IPO lead).
- Hahn brings nearly 30 years of CFO-level experience; certified CPA in Maryland and North Carolina.

## SEC filing metadata
- accession: 0001193125-25-237854
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312525237854/0001193125-25-237854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312525237854/d847935d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-237854
- JSON: https://secwatch.observer/filing/0001193125-25-237854.json
- Plain text: https://secwatch.observer/filing/0001193125-25-237854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.